FANCE (Fanconi anemia complementation group E) is a critical component of the Fanconi anemia (FA) complex that functions in DNA interstrand cross-link repair. The protein acts as a molecular bridge between the FA complex and FANCD2, and is required for the nuclear accumulation of FANCC, facilitating proper localization and assembly of repair machinery. Mutations in FANCE cause Fanconi anemia complementation group E, a rare inherited disorder characterized by genomic instability and cancer predisposition. In the context of hereditary cancer screening, FANCE has been identified as a candidate gene in breast/ovarian cancer families, with loss-of-function variants detected in affected individuals 1. While FANCE is not considered a high-actionability gene like BRCA1/2, its detection in multigene panel testing may contribute to understanding cancer risk in BRCA1/2-negative families. The clinical significance of FANCE variants in cancer predisposition requires further investigation, as the gene's primary association remains with Fanconi anemia rather than common malignancies. Further functional studies are needed to establish definitive genotype-phenotype correlations and clinical management recommendations.